PharmaBiome has developed a drug development platform for targeted microbiome therapeutics, combining dynamic microbiome analysis and co-cultivation-based assembly technology. By actively engineering composition and activity of our multi-strain consortia we solve current translational shortcomings.

Products, services, technology

The platform has extensively been validated preclinically and will be advanced into humans based on two strategically selected indications: The first and most progressed is acute Graft vs. Host Disease (aGvHD), followed by Ulcerative Colitis (UC). Both first in human studies are planned for 2024/25.

Cooperation possibilities

As microbiome experts, we are looking to leverage the potential of our platform through industrial partnerships to bring microbiome therapeutics into clinics. We are active in the fields of oncology as well as inflammatory bowel diseases and can address indications of interest for a partner.

Some insights

Wagistrasse 27, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland